The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis

Matrix Biology

Volumn 64, Issue , 2017, Pages 40-53

  Andreuzzi, Eva ^a   Colladel, Roberta ^a   Pellicani, Rosanna ^a   Tarticchio, Giulia ^a   Cannizzaro, Renato ^a   Spessotto, Paola ^a   Bussolati, Benedetta ^b   Brossa, Alessia ^b   De Paoli, Paolo ^a   Canzonieri, Vincenzo ^a   Iozzo, Renato V ^c   Colombatti, Alfonso ^a   Mongiat, Maurizio ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Endothelial cells; Tumor microenvironment

Indexed keywords

ANGIOSTATIC PROTEIN; GELATINASE B; MULTIMERIN 2; UNCLASSIFIED DRUG; EMILIN3 PROTEIN, HUMAN; GELATINASE A; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; CELL MIGRATION; CORRELATION ANALYSIS; DOWN REGULATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSEUDOPODIUM; CELL LINE; CELL MOTION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HT-29 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIGENS, SURFACE; BIOMARKERS, TUMOR; CELL LINE; CELL MOVEMENT; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOLYSIS; PSEUDOPODIA;

EID: 85018162549     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2017.04.002     Document Type: Article

References (59)

1. Risau, W., Mechanisms of angiogenesis. Nature 386 (1997), 671–674.
2. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000), 389–395.
3. Carmeliet, P., Angiogenesis in health and disease. Nat. Med. 9 (2003), 653–660.
4. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
5. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971), 1182–1186.
6. Folkman, J., Angiogenesis. Annu. Rev. Med. 57 (2006), 1–18.
7. Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
8. Cascone, T., Heymach, J.V., Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J. Clin. Oncol. 30 (2012), 441–444.
9. Chung, A.S., Lee, J., Ferrara, N., Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10 (2010), 505–514.
10. Ohtsu, A., Shah, M.A., Van, C.E., Rha, S.Y., Sawaki, A., Park, S.R., Lim, H.Y., Yamada, Y., Wu, J., Langer, B., Starnawski, M., Kang, Y.K., Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29 (2011), 3968–3976.
11. Okines, A., Cunningham, D., Current perspective: bevacizumab in colorectal cancer–a time for reappraisal?. Eur. J. Cancer 45 (2009), 2452–2461.
12. Ferrara, N., VEGF as a therapeutic target in cancer. Oncology 69:Suppl. 3 (2005), 11–16.
13. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004), 2335–2342.
14. Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., Norman, A.R., Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358 (2008), 36–46.
15. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009), 232–239.
16. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., Inoue, M., Bergers, G., Hanahan, D., Casanovas, O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009), 220–231.
17. Van, C.E., Tabernero, J., Lakomy, R., Prenen, H., Prausova, J., Macarulla, T., Ruff, P., van Hazel, G.A., Moiseyenko, V., Ferry, D., McKendrick, J., Polikoff, J., Tellier, A., Castan, R., Allegra, C., Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30 (2012), 3499–3506.
18. Grothey, A., Van, C.E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouche, O., Mineur, L., Barone, C., Adenis, A., Tabernero, J., Yoshino, T., Lenz, H.J., Goldberg, R.M., Sargent, D.J., Cihon, F., Cupit, L., Wagner, A., Laurent, D., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
19. Garcia-Carbonero, R., Rivera, F., Maurel, J., Ayoub, J.P., Moore, M.J., Cervantes, A., Asmis, T.R., Schwartz, J.D., Nasroulah, F., Ballal, S., Tabernero, J., An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 19 (2014), 350–351.
20. Mongiat, M., Marastoni, S., Ligresti, G., Lorenzon, E., Schiappacassi, M., Perris, R., Frustaci, S., Colombatti, A., The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment. Neoplasia 12 (2010), 294–304.
21. Adams, J.C., Lawler, J., The thrombospondins. Cold Spring Harb. Perspect. Biol., 3, 2011, a009712.
22. Mongiat, M., Andreuzzi, E., Tarticchio, G., Paulitti, A., Extracellular matrix, a hard player in angiogenesis. Int. J. Mol. Sci., 17, 2016.
23. Torres, A., Gubbiotti, M.A., Iozzo, R.V., Decorin-inducible Peg3 evokes beclin 1-mediated autophagy and thrombospondin 1-mediated angiostasis. J. Biol. Chem., 2017.
24. Pozzi, A., Yurchenco, P.D., Iozzo, R.V., The nature and biology of basement membranes. Matrix Biol. 57-58 (2017), 1–11.
25. Gubbiotti, M.A., Neill, T., Iozzo, R.V., A current view of perlecan in physiology and pathology: a mosaic of functions. Matrix Biol. 57-58 (2017), 285–298.
26. Colladel, R., Pellicani, R., Andreuzzi, E., Paulitti, A., Tarticchio, G., Todaro, F., Colombatti, A., Mongiat, M., MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth. Oncotarget 7 (2016), 2022–2037.
27. Lorenzon, E., Colladel, R., Andreuzzi, E., Marastoni, S., Todaro, F., Schiappacassi, M., Ligresti, G., Colombatti, A., Mongiat, M., MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene 31 (2012), 3136–3147.
28. Apte, S.S., Parks, W.C., Metalloproteinases: a parade of functions in matrix biology and an outlook for the future. Matrix Biol. 44-46 (2015), 1–6.
29. Fang, J., Shing, Y., Wiederschain, D., Yan, L., Butterfield, C., Jackson, G., Harper, J., Tamvakopoulos, G., Moses, M.A., Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 3884–3889.
30. Belotti, D., Paganoni, P., Manenti, L., Garofalo, A., Marchini, S., Taraboletti, G., Giavazzi, R., Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63 (2003), 5224–5229.
31. Deryugina, E.I., Quigley, J.P., Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta 2010 (1803), 103–120.
32. Arpino, V., Brock, M., Gill, S.E., The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 44-46 (2015), 247–254.
33. Wells, J.M., Gaggar, A., Blalock, J.E., MMP generated matrikines. Matrix Biol. 44-46 (2015), 122–129.
34. Deryugina, E.I., Quigley, J.P., Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 44-46 (2015), 94–112.
35. Rohani, M.G., Parks, W.C., Matrix remodeling by MMPs during wound repair. Matrix Biol. 44-46 (2015), 113–121.
36. Duarte, S., Baber, J., Fujii, T., Coito, A.J., Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol. 44-46 (2015), 147–156.
37. Eckhard, U., Huesgen, P.F., Schilling, O., Bellac, C.L., Butler, G.S., Cox, J.H., Dufour, A., Goebeler, V., Kappelhoff, R., Keller, U.A., Klein, T., Lange, P.F., Marino, G., Morrison, C.J., Prudova, A., Rodriguez, D., Starr, A.E., Wang, Y., Overall, C.M., Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol. 49 (2016), 37–60.
38. Braghetta, P., Ferrari, A., De, G.P., Zanetti, M., Volpin, D., Bonaldo, P., Bressan, G.M., Overlapping, complementary and site-specific expression pattern of genes of the EMILIN/Multimerin family. Matrix Biol. 22 (2004), 549–556.
39. Colombatti, A., Spessotto, P., Doliana, R., Mongiat, M., Bressan, G.M., Esposito, G., The EMILIN/Multimerin family. Front. Immunol., 2, 2011, 93.
40. Doliana, R., Canton, A., Bucciotti, F., Mongiat, M., Bonaldo, P., Colombatti, A., Structure, chromosomal localization, and promoter analysis of the human elastin microfibril interfase located proteIN (EMILIN) gene. J. Biol. Chem. 275 (2000), 785–792.
41. Christian, S., Ahorn, H., Novatchkova, M., Garin-Chesa, P., Park, J.E., Weber, G., Eisenhaber, F., Rettig, W.J., Lenter, M.C., Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium. J. Biol. Chem. 276 (2001), 48588–48595.
42. Moses, M.A., The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15 (1997), 180–189.
43. Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002), 161–174.
44. van Hinsbergh, V.W., Engelse, M.A., Quax, P.H., Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 716–728.
45. Handsley, M.M., Edwards, D.R., Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115 (2005), 849–860.
46. Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., Hanahan, D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000), 737–744.
47. Poimenidi, E., Theodoropoulou, C., Koutsioumpa, M., Skondra, L., Droggiti, E., van den Broek, M., Koolwijk, P., Papadimitriou, E., Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner. Vasc. Pharmacol. 80 (2016), 11–19.
48. Noy, P.J., Lodhia, P., Khan, K., Zhuang, X., Ward, D.G., Verissimo, A.R., Bacon, A., Bicknell, R., Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene 34 (2015), 5821–5831.
49. Lee, S., Rho, S.S., Park, H., Park, J.A., Kim, J., Lee, I.K., Koh, G.Y., Mochizuki, N., Kim, Y.M., Kwon, Y.G., Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis. J. Clin. Invest. 127 (2017), 457–471.
50. Chung, S., Dwabe, S., Elshimali, Y., Sukhija, H., Aroh, C., Vadgama, J.V., Identification of novel biomarkers for metastatic colorectal cancer using angiogenesis-antibody array and intracellular signaling array. PLoS One, 10, 2015, e0134948.
51. Rundhaug, J.E., Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9 (2005), 267–285.
52. Shield-Artin, K.L., Bailey, M.J., Oliva, K., Liovic, A.K., Barker, G., Dellios, N.L., Reisman, S., Ayhan, M., Rice, G.E., Identification of ovarian cancer-associated proteins in symptomatic women: a novel method for semi-quantitative plasma proteomics. Proteomics Clin. Appl. 6:3-4 (2012), 170–181, 10.1002/prca.201100008 (n/a).
53. Soltermann, A., Ossola, R., Kilgus-Hawelski, S., von, E.A., Suter, T., Aebersold, R., Moch, H., N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer 114 (2008), 124–133.
54. Zanivan, S., Maione, F., Hein, M.Y., Hernandez-Fernaud, J.R., Ostasiewicz, P., Giraudo, E., Mann, M., SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol. Cell. Proteomics 12 (2013), 3599–3611.
55. Huber, M.A., Kraut, N., Schweifer, N., Dolznig, H., Peter, R.U., Schubert, R.D., Scharffetter-Kochanek, K., Pehamberger, H., Garin-Chesa, P., Expression of stromal cell markers in distinct compartments of human skin cancers. J. Cutan. Pathol. 33 (2006), 145–155.
56. Grange, C., Bussolati, B., Bruno, S., Fonsato, V., Sapino, A., Camussi, G., Isolation and characterization of human breast tumor-derived endothelial cells. Oncol. Rep. 15 (2006), 381–386.
57. Fiorio, P.A., Brossa, A., Bernardini, M., Genova, T., Grolez, G., Villers, A., Leroy, X., Prevarskaya, N., Gkika, D., Bussolati, B., Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib. BMC Cancer, 14, 2014, 939.
58. Bussolati, B., Deambrosis, I., Russo, S., Deregibus, M.C., Camussi, G., Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 17 (2003), 1159–1161.
59. Aplin, A.C., Fogel, E., Zorzi, P., Nicosia, R.F., The aortic ring model of angiogenesis. Methods Enzymol. 443 (2008), 119–136.